Carl Zeiss Meditec AG (AFX.DE)
EUR 56.6
(-1.91%)
EUR 56.6
(-1.91%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 327.13 Million EUR | 3.57% |
| 2022 | 413.08 Million EUR | 18.56% |
| 2021 | 348.41 Million EUR | 68.64% |
| 2020 | 206.6 Million EUR | -13.22% |
| 2019 | 238.06 Million EUR | 20.77% |
| 2018 | 197.13 Million EUR | 7.88% |
| 2017 | 182.72 Million EUR | 18.4% |
| 2016 | 154.33 Million EUR | 18.18% |
| 2015 | 130.59 Million EUR | 8.19% |
| 2014 | 120.7 Million EUR | -9.84% |
| 2013 | 133.87 Million EUR | 8.93% |
| 2012 | 122.9 Million EUR | 18.67% |
| 2011 | 103.56 Million EUR | 19.39% |
| 2010 | 86.74 Million EUR | 14.01% |
| 2009 | 76.08 Million EUR | 12.17% |
| 2008 | 67.83 Million EUR | -3.59% |
| 2007 | 70.35 Million EUR | 46.32% |
| 2006 | 48.08 Million EUR | 34.57% |
| 2005 | 35.73 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 108.2 Million EUR | 84.64% |
| 2024 Q3 | 54.69 Million EUR | -49.73% |
| 2024 Q1 | 58.6 Million EUR | -51.01% |
| 2023 Q4 | 119.61 Million EUR | -11.8% |
| 2023 FY | 427.81 Million EUR | 3.57% |
| 2023 Q1 | 59.8 Million EUR | -58.23% |
| 2023 Q2 | 96.17 Million EUR | 60.83% |
| 2023 Q3 | 135.61 Million EUR | 41.0% |
| 2022 Q1 | 74.4 Million EUR | -18.07% |
| 2022 Q4 | 143.18 Million EUR | 46.04% |
| 2022 Q3 | 98.04 Million EUR | -6.02% |
| 2022 Q2 | 104.32 Million EUR | 40.22% |
| 2022 FY | 413.08 Million EUR | 18.56% |
| 2021 Q1 | 73.4 Million EUR | 11.8% |
| 2021 FY | 348.41 Million EUR | 68.64% |
| 2021 Q3 | 120.11 Million EUR | 34.55% |
| 2021 Q4 | 90.81 Million EUR | -24.39% |
| 2021 Q2 | 89.27 Million EUR | 21.62% |
| 2020 Q1 | 56.8 Million EUR | -29.49% |
| 2020 Q3 | 9.39 Million EUR | -79.44% |
| 2020 Q4 | 65.65 Million EUR | 598.57% |
| 2020 FY | 206.6 Million EUR | -13.22% |
| 2020 Q2 | 45.7 Million EUR | -19.54% |
| 2019 Q1 | 48.1 Million EUR | -22.95% |
| 2019 FY | 238.06 Million EUR | 20.77% |
| 2019 Q3 | 73.74 Million EUR | 18.4% |
| 2019 Q2 | 62.28 Million EUR | 29.49% |
| 2019 Q4 | 80.55 Million EUR | 9.24% |
| 2018 Q3 | 46.45 Million EUR | -5.89% |
| 2018 FY | 197.13 Million EUR | 7.88% |
| 2018 Q4 | 62.43 Million EUR | 34.38% |
| 2018 Q2 | 49.36 Million EUR | 27.23% |
| 2018 Q1 | 38.8 Million EUR | -2.52% |
| 2017 FY | 182.72 Million EUR | 18.4% |
| 2017 Q3 | 37.41 Million EUR | -26.46% |
| 2017 Q2 | 50.88 Million EUR | 15.12% |
| 2017 Q1 | 44.2 Million EUR | 0.79% |
| 2017 Q4 | 39.8 Million EUR | 6.37% |
| 2016 Q1 | 32.23 Million EUR | -21.58% |
| 2016 Q4 | 43.85 Million EUR | 24.6% |
| 2016 Q3 | 35.19 Million EUR | -18.24% |
| 2016 Q2 | 43.05 Million EUR | 33.57% |
| 2016 FY | 154.33 Million EUR | 18.18% |
| 2015 Q2 | 33.11 Million EUR | 18.78% |
| 2015 Q3 | 28.49 Million EUR | -13.95% |
| 2015 Q4 | 41.09 Million EUR | 44.23% |
| 2015 FY | 130.59 Million EUR | 8.19% |
| 2015 Q1 | 27.88 Million EUR | -2.38% |
| 2014 Q3 | 28.48 Million EUR | -23.36% |
| 2014 Q2 | 37.16 Million EUR | 40.28% |
| 2014 FY | 120.7 Million EUR | -9.84% |
| 2014 Q1 | 26.49 Million EUR | -35.95% |
| 2014 Q4 | 28.56 Million EUR | 0.26% |
| 2013 Q4 | 41.36 Million EUR | 45.84% |
| 2013 Q2 | 32.91 Million EUR | 5.4% |
| 2013 Q1 | 31.23 Million EUR | -8.98% |
| 2013 FY | 133.87 Million EUR | 8.93% |
| 2013 Q3 | 28.36 Million EUR | -13.83% |
| 2012 FY | 122.9 Million EUR | 18.67% |
| 2012 Q3 | 27.49 Million EUR | -16.23% |
| 2012 Q4 | 34.31 Million EUR | 24.8% |
| 2012 Q2 | 32.81 Million EUR | 16.06% |
| 2012 Q1 | 28.27 Million EUR | 1.35% |
| 2011 Q1 | 24.01 Million EUR | -10.38% |
| 2011 Q4 | 27.9 Million EUR | 14.61% |
| 2011 Q3 | 24.34 Million EUR | -10.87% |
| 2011 FY | 103.56 Million EUR | 19.39% |
| 2011 Q2 | 27.31 Million EUR | 13.75% |
| 2010 Q1 | 18.68 Million EUR | -16.86% |
| 2010 Q3 | 20.67 Million EUR | 0.36% |
| 2010 Q2 | 20.59 Million EUR | 10.27% |
| 2010 Q4 | 26.79 Million EUR | 29.6% |
| 2010 FY | 86.74 Million EUR | 14.01% |
| 2009 FY | 76.08 Million EUR | 12.17% |
| 2009 Q4 | 22.46 Million EUR | 52.49% |
| 2009 Q3 | 14.73 Million EUR | -15.3% |
| 2009 Q2 | 17.39 Million EUR | -19.04% |
| 2009 Q1 | 21.48 Million EUR | 0.0% |
| 2008 FY | 67.83 Million EUR | -3.59% |
| 2007 FY | 70.35 Million EUR | 46.32% |
| 2006 FY | 48.08 Million EUR | 34.57% |
| 2005 FY | 35.73 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| SCHOTT Pharma AG & Co. KGaA | 192.38 Million EUR | -70.044% |
| Fielmann Aktiengesellschaft | 286.54 Million EUR | -14.165% |
| Gerresheimer AG | 213.39 Million EUR | -53.304% |
| Sartorius Aktiengesellschaft | 543.2 Million EUR | 39.776% |
| Sartorius Aktiengesellschaft | 543.2 Million EUR | 39.776% |